Direct-acting antivirals for chronic hepatitis C-Reference-Cited by-同舟云学术

Direct-acting antivirals for chronic hepatitis C

Published:2017-06-06 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Jakobsen Janus C¹²,Nielsen Emil Eik³,Feinberg Joshua³,Katakam Kiran Kumar⁴,Fobian Kristina³,Hauser Goran⁵,Poropat Goran⁵,Djurisic Snezana⁴,Weiss Karl Heinz⁶,Bjelakovic Milica⁷,Bjelakovic Goran⁸,Klingenberg Sarah Louise¹,Liu Jian Ping⁹,Nikolova Dimitrinka¹,Koretz Ronald L¹⁰,Gluud Christian¹

Affiliation:

1. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; The Cochrane Hepato-Biliary Group; Blegdamsvej 9 Copenhagen Sjaelland Denmark DK-2100

2. Holbaek Hospital; Department of Cardiology; Holbaek Denmark 4300

3. Department 7812, Rigshospitalet, Copenhagen University Hospital; Copenhagen Trial Unit, Centre for Clinical Intervention Research; Blegdamsvej 9 Copenhagen Denmark 2100

4. Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital; Blegdamsvej 9 Copenhagen Denmark 2100

5. Clinical Hospital Centre Rijeka; Department of Gastroenterology; Kresimirova 42 Rijeka Croatia 51 000

6. Heidelberg University Hospital; Internal Medicine IV: Gastroenterology, Infectious Diseases, Toxicology; Im Neuenheimer Feld 410 Heidelberg Germany D-69120

7. University of Nis; Medical Faculty; Boulevard Dr Zorana Djindjica 81 Nis Serbia 18000

8. Medical Faculty, University of Nis; Department of Internal Medicine; Zorana Djindjica 81 Nis Serbia 18000

9. Beijing University of Chinese Medicine; Centre for Evidence-Based Chinese Medicine; 11 Bei San Huan Dong Lu, Chaoyang District Beijing China 100029

10. 16847 Colven Road Granada Hills CA USA CA 91344

Publisher

Wiley

Subject

Pharmacology (medical)

Reference765 articles.

1. Cost-effectiveness of telaprevir combination therapy for chronic hepatitis C;Brogan;PLoS ONE,2014

2. Curtis S Cure S Gavart S Dearden L Fleischmann J Ouwens M The cost-effectiveness of telaprevir (TVR) in combination with pegylated interferon-alfa and ribavirin (PR) for the treatment of genotype 1 chronic hepatitis C patients Journal of Hepatology 2012 S434

3. Telaprevir in combination with peginterferon alfa-2a and ribavirin: analyses of pre-defined subpopulations in the phase 3 ADVANCE trial;Bisceglie;Gastroenterology,2011

4. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 Advance study;Dusheiko;Gut,2011

5. Telaprevir in combination with peginterferon alfa-2a and ribavirin increased sustained virologic response in genotype 1 chronic HCV and allowed for shorter treatment duration in treatment-naive and prior relapser patients;Everson;American Journal of Gastroenterology,2011

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs;Harm Reduction Journal;2024-08-28

2. Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis;BMJ Mental Health;2024-01

3. Progression of the FIB-4 index among patients with chronic HCV infection and early liver disease;BMJ Open Gastroenterology;2023-12

4. Bad research is not all bad;Trials;2023-10-20

5. Identification of the Genotypes Circulating in the Ecuadorian Population Infected with the Hepatitis C Virus (HCV);Risk Management and Healthcare Policy;2023-08